Combination of cyamemazine and an atypical neuroleptic
AssigneeAventis Pharma S.A.
InventorsMichel Dib, Cyrille Leperlier
Life of this patent
Estimating the term…
Abstract
The present invention relates to the combination of cyamemazine and an atypical neuroleptic, or a pharmaceutically acceptable salt thereof, and to the use thereof in the treatment of schizophrenia, and in particular of acute episodes of schizophrenia.
Claims21
A pharmaceutical composition comprising at least about 50 mg to about 600 mg of cyamemazine in combination with an atypical neuroleptic selected from the group consisting of sertindole, quetiapine and ziprasidone or a pharmaceutically acceptable salt thereof, optionally in combination with a pharmaceutically acceptable carrier.
A method for treating a patient suffering from schizophrenic disorders comprising administering to said patient an effective amount of a combination of cyamemazine and an atypical neuroleptic selected from the group consisting of sertindole, quetiapine and ziprasidone or a pharmaceutically acceptable salt thereof, optionally in combination with a pharmaceutically acceptable carrier.
A method for treating a patient suffering from acute episodes of schizophrenia comprising administering to said patient an effective amount of a combination of cyamemazine and an atypical neuroleptic selected from the group consisting of sertindole, quetiapine and ziprasidone or a pharmaceutically acceptable salt thereof, optionally in combination with a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.